// App-Quantinova.ai

TPS6104 : Patritumab (P) or placebo (PBO) plus cetuximab (C) and platinum-based therapy in squamous cell carcinoma of the head and neck (SCCHN): a phase 2 study.

Researchers

Presenter

  • Kevin J. Harrington

Principal Investigators

  • Martin David Forster

  • Magnus Dillon

  • Lorna Grove

  • Sola Adeleke

  • Shuquan Chen

  • Jane S. Diamond

  • Henrik Hannus

  • Kandance Cooper

  • Jonathan Greenberg

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Kings College London, London, United Kingdom

  • Daiichi Sankyo, Inc., Edison, NJ

  • Daiichi Sankyo, Buckinghamshire, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • N/A

Drug/Treatment

  • Carboplatin

  • Patritumab

  • Erbitux

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • II

Study Id's

  • NCT02633800

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved